Welcome to our dedicated page for Biorestorative Therapies news (Ticker: BRTX), a resource for investors and traders seeking the latest updates and insights on Biorestorative Therapies stock.
BioRestorative Therapies, Inc. (NASDAQ: BRTX) is a regenerative medicine company focused on stem cell-based therapies and products, and its news flow reflects activity across clinical development, intellectual property, commercialization, and capital markets. The company develops therapeutic products using adult stem cell protocols, with core programs in disc and spine disease, metabolic disorders, and a commercial BioCosmeceutical platform.
News about BRTX often centers on its disc/spine program (brtxDISC™) and lead cell therapy candidate BRTX-100. Recent announcements include Fast Track designation from the U.S. Food and Drug Administration (FDA) for the BRTX-100 Phase 2 trial in chronic lumbar disc disease and the granting of a Type B meeting with the FDA to discuss a potential accelerated Biologics License Application approval pathway. Updates also cover blinded Phase 2 clinical data presented at scientific meetings and the status of enrollment and trial progress.
Another key news theme is the ThermoStem® metabolic program, where BioRestorative has reported milestones such as a Notice of Allowance from the Japanese Patent Office for its allogeneic, off-the-shelf brown adipose-derived stem cell technology designed to treat obesity and metabolic disorders. Press releases describe how this intellectual property strengthens protection for cell-based approaches that aim to generate brown adipose tissue and utilize exosomes secreted by brown adipose-derived stem cells.
Investors following BRTX news will also see coverage of the company’s BioCosmeceutical platform, including commercial developments for its cell-based secretome serum, as well as corporate events such as equity financings, stock repurchase authorizations, conference presentations, and quarterly financial results. This page aggregates these updates so readers can track BioRestorative’s clinical, commercial, and financial disclosures in one place.
BioRestorative Therapies (OTC: BRTX) announced the issuance of a significant patent by the Japanese Patent Office for its ThermoStem® Program, which focuses on methodologies for deriving brown adipocytes from human brown adipose-derived stem cells. The patent underscores the potential of brown fat in improving metabolic processes, including calorie burning and glucose regulation. CEO Lance Alstodt highlighted the growing value of their intellectual property. The company is utilizing stem cell protocols for various therapies, including treatments for disc/spine diseases and obesity.
Summary not available.
BioRestorative Therapies (OTC: BRTX) announces its annual stockholders meeting on August 17, 2021, at 10 a.m. EDT. Key proposals for vote include the reincorporation from Delaware to Nevada and a reverse stock split. Majority approval is required for these changes. Stockholders of record as of June 24, 2021, are encouraged to vote online or attend in person. The company focuses on developing stem cell-based therapies, with lead product BRTX-100 targeting chronic lower back pain.
BioRestorative Therapies (OTC: BRTX) announced the filing of a registration statement on Form S-1 with the SEC for a proposed underwritten public offering of its securities. The offering's completion depends on the registration's effectiveness and market conditions. If successful, the net proceeds will fund clinical trials for BRTX-100, research and development for the metabolic ThermoStem Program, and general corporate expenses.
BioRestorative Therapies invites investors to attend its presentation at the Emerging Growth Conference on June 9, 2021, at 10:45 AM Eastern Time. The event allows interaction with CEO Lance Alstodt and VP of R&D Francisco Silva. Attendees can ask questions, and a recording will be available post-event. BioRestorative focuses on stem cell therapies, with its leading product BRTX-100 targeting chronic lower back pain. The conference serves as a platform for public companies to present innovative solutions to investors.
BioRestorative Therapies, Inc. (OTC: BRTX) announced the expansion of its Melville, NY research labs for clinical production of cell therapies.
The new cGMP facility will support the Phase 2 clinical trial for BRTX-100 and the ThermoStem® program, enhancing internal manufacturing capabilities.
As part of this initiative, the company plans to hire more employees, aligning operations with FDA and EMA regulations for clinical-grade cell production.
BioRestorative Therapies, Inc. (OTC: BRTX) announced the filing of its Annual Report on Form 10-K for 2020, achieving compliance with SEC requirements. This filing removed the 'stop sign' from its OTC profile, indicating current public information availability. CEO Lance Alstodt expressed optimism regarding the company's positioning for funding opportunities for its phase 2 clinical trial and advances in its metabolics program. The company emphasizes a focus on clinical programs to drive future value for shareholders.
BioRestorative Therapies (OTC: BRTX) announced the appointment of Dr. Nickolay V. Kukekov to its Board of Directors, effective March 18, 2021. Dr. Kukekov brings extensive experience in the Emerging Growth Lifesciences sector and capital markets, focusing on biotech company growth. His appointment is seen as pivotal for pursuing strategic objectives, including capital raising for the Phase 2 clinical study of BRTX-100, targeting chronic lower back pain. BioRestorative aims to strengthen its market position in stem cell therapies.
BioRestorative Therapies, Inc. (OTC: BRTX) announced a notice of allowance from the U.S. Patent Office for a patent related to its ThermoStem® Program, granted on March 22, 2021. This patent involves methodologies for generating exosomes from brown adipose-derived stem cells, which may offer therapeutic benefits in treating various diseases. The exosome market is projected to reach $368 million by 2022. The CEO emphasized the importance of this patent for protecting their intellectual property and driving the company's growth strategy.
BioRestorative Therapies (OTC: BRTX) announced on March 22, 2021, that it received notices of allowance for three patent applications related to its ThermoStem® Program from the United States Patent Office and various international agencies. The patents cover a specific human brown adipose tissue-derived stem cell with potential therapeutic applications for degenerative and metabolic disorders. These allowances are expected to enhance the company's intellectual property and therapeutic pipeline, as stated by company executives.